GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » Gross Profit

Relief Therapeutics Holding (Relief Therapeutics Holding) Gross Profit

: $-8.39 Mil (TTM As of Jun. 2023)
View and export this data going back to 1990. Start your Free Trial

Relief Therapeutics Holding's gross profit for the six months ended in Jun. 2023 was $2.49 Mil. Relief Therapeutics Holding's gross profit for the trailing twelve months (TTM) ended in Jun. 2023 was $-8.39 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Relief Therapeutics Holding's gross profit for the six months ended in Jun. 2023 was $2.49 Mil. Relief Therapeutics Holding's Revenue for the six months ended in Jun. 2023 was $3.36 Mil. Therefore, Relief Therapeutics Holding's Gross Margin % for the quarter that ended in Jun. 2023 was 74.23%.

Relief Therapeutics Holding had a gross margin of 74.23% for the quarter that ended in Jun. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Relief Therapeutics Holding was 90.27%. The lowest was -495.42%. And the median was -44.51%.


Relief Therapeutics Holding Gross Profit Historical Data

The historical data trend for Relief Therapeutics Holding's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Gross Profit
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 -0.07 -15.39 -17.86 -8.12

Relief Therapeutics Holding Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Profit Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -17.86 2.65 -10.88 2.49

Competitive Comparison

For the Biotechnology subindustry, Relief Therapeutics Holding's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding Gross Profit Distribution

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Gross Profit distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Gross Profit falls into.



Relief Therapeutics Holding Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Relief Therapeutics Holding's Gross Profit for the fiscal year that ended in Dec. 2022 is calculated as

Gross Profit (A: Dec. 2022 )=Revenue - Cost of Goods Sold
=6.527 - 14.644
=-8.12

Relief Therapeutics Holding's Gross Profit for the quarter that ended in Jun. 2023 is calculated as

Gross Profit (Q: Jun. 2023 )=Revenue - Cost of Goods Sold
=3.357 - 0.865
=2.49

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-8.39 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Relief Therapeutics Holding's Gross Margin % for the quarter that ended in Jun. 2023 is calculated as

Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=2.49 / 3.357
=74.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Relief Therapeutics Holding  (OTCPK:RLFTF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Relief Therapeutics Holding had a gross margin of 74.23% for the quarter that ended in Jun. 2023 => Durable competitive advantage


Relief Therapeutics Holding Gross Profit Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding (Relief Therapeutics Holding) Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.

Relief Therapeutics Holding (Relief Therapeutics Holding) Headlines

From GuruFocus

Relief Therapeutics to Participate in January Investor Meetings

By ACCESSWIRE ACCESSWIRE 12-14-2022